Our systematic review and meta-analysis suggests that PPAR agonists exhibit superior efficacy as compared with placebo in reducing key biochemical markers in PBC including ALP, GGT, TBil, and triglyceride levels, which indicates beneficial effects on liver function and overall metabolic profile. Here, PPARA is linked to primary biliary cholangitis.